Anti-EGFR aptameric construct GR20HH for controllable delivery of doxorubicin into glioblastoma cells
- Autores: Ivanov B.1, Antipova O.1, Sliman Y.2,3, Samoylenkova N.2, Pronin I.2, Pavlova G.2,4,5, Kopylov A.1
-
Afiliações:
- Lomonosov Moscow State University
- Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia
- Moscow institute of physics and technology, national research university
- Institute of Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences
- Sechenov First Moscow State Medical University
- Edição: Volume 74, Nº 1 (2024)
- Páginas: 100-108
- Seção: ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ
- URL: https://journals.rcsi.science/0044-4677/article/view/259310
- DOI: https://doi.org/10.31857/S0044467724010107
- ID: 259310
Citar
Resumo
This publication describes research on a possibility of controllable delivery of doxorubicin (DOX) into glioblastoma (GB) cells, being inside non-covalent construct with anti-EGFR DNA aptamer by intercalating into artificially created duplex. The construct has been made with previously described DNA aptamer GR20 (46 nucleotides), with 3’-end 18 nucleotides extension (GR20h), which was hybridized with the complementary DNA oligonucleotides (h).
The duplex assembly is effective, the construct GR20hh is stable at 37 ºС, Tm = 59 ºС. DOX is intercalated into the construct. By applying xCelligence Real-Time Cell Analysis (RTCA) combined with self-created data processing, it has been shown that during a treatment of cell culture DOX, inside the non-covalent construct GR20hh – DOX, saves cytotoxic ability, though a kinetics of toxic action of the complex on GB cells is completely different from the kinetics of DOX along.
The unique approach and the data are the bases for a development of both a regulation and a targeting of DOX cytotoxic activity toward specific GB cells.
Palavras-chave
Texto integral
Sobre autores
B. Ivanov
Lomonosov Moscow State University
Autor responsável pela correspondência
Email: ivanovb661@yandex.ru
Chemistry Department
Rússia, MoscowO. Antipova
Lomonosov Moscow State University
Email: ivanovb661@yandex.ru
Chemistry Department
Rússia, MoscowY. Sliman
Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia; Moscow institute of physics and technology, national research university
Email: ivanovb661@yandex.ru
Rússia, Moscow; Dolgoprudny
N. Samoylenkova
Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia
Email: ivanovb661@yandex.ru
Rússia, Moscow
I. Pronin
Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia
Email: ivanovb661@yandex.ru
Rússia, Moscow
G. Pavlova
Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia; Institute of Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences; Sechenov First Moscow State Medical University
Email: ivanovb661@yandex.ru
Rússia, Moscow; Moscow; Moscow
A. Kopylov
Lomonosov Moscow State University
Email: ivanovb661@yandex.ru
Chemistry Department
Rússia, MoscowBibliografia
- Ai S., Duan J., Liu X., Bock S., Tian Y., Huang Z. Biological evaluation of a novel doxorubicin – peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol. Pharm. 2011. 8 (2): 375–386.
- Akhtar N., Mohammed H. A., Yusuf M., Al-Subaiyel A., Sulaiman G. M., Khan R. A. SPIONs conjugate supported anticancer drug doxorubicin’s delivery: current status, challenges, and prospects. Nanomaterials. 2022. 12 (20): 3686.
- Alieva R. R., Zavyalova E. G., Tashlitsky V. N., Kopylov A. M. Quantitative characterization of oligomeric state of G-quadruplex antithrombin aptamers by size exclusion HPLC. Mendeleev Communications. 2019. 29 (4): 424–425.
- Horbinski C., Berger T., Packer R. J., Wen, P. Y. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat. Rev. Neurol. 2022. 18 (9): 515–529.
- Kopylov A. M., Fab L. V., Antipova O., Savchenko E. A., Revishchin A. V., Parshina V. V., Pavlova S. V., Kireev I. I., Golovin A. V., Usachev D. Y., Pavlova G. V. RNA aptamers for theranostics of glioblastoma of human brain. Biochemistry (Moscow). 2021. 86: 1012–1024.
- Liu T., Song P., Märcher A., Kjems J., Yang C., Gothelf K. V. Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab–DNA conjugates. Chem. Bio. Chem. 2019. 20 (8): 1014–1018.
- Martins‐Teixeira M.B., Carvalho I. Antitumour anthracyclines: progress and perspectives. Chem. Med. Chem. 2020. 15 (11): 933–948.
- Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004. 56 (2): 185–229.
- Pérez-Arnaiz C., Busto N., Leal J. M., García B. New insights into the mechanism of the DNA/doxorubicin interaction. J. Phys. Chem B. 2014. 118 (5): 1288–1295.
- Pugazhendhi A., Edison T. N.J.I., Velmurugan B. K., Jacob J. A., Karuppusamy I. Toxicity of doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018. 200: 26–30.
- Zavyalova E. G., Legatova V. A., Alieva R. S., Zalevsky A. O., Tashlitsky V. N., Arutyunyan A. M., Kopylov A. M. Putative mechanisms underlying high inhibitory activities of bimodular DNA aptamers to thrombin. Biomolecules. 2019. 9 (2): 41.
- Zavyalova E., Turashev A., Novoseltseva A., Legatova V., Antipova O., Savchenko E., Balk S., Golovin A., Pavlova G., Kopylov A. Pyrene-modified DNA aptamers with high affinity to wild-type EGFR and EGFRvIII. Nucl. Acid Therap. 2020. 30 (3): 175–187.